More Lawsuits Claim Reglan Tardive Dyskinesia

Alexander Cross | November 2nd, 2011 | Posted in Reglan Lawsuit News

Reglan is commonly prescribed for the treatment of gastrointestinal disorders, such as nausea, gastric reflux, heartburn, or morning sickness associated with pregnancy. The drug is also linked to serious Reglan side effects, such as Reglan tardive dyskinesia. Metoclopramide, the main ingredient of Reglan, was developed during the 1960’s in Europe. It was designed as a dopamine antagonist operating on a specific dopamine receptor known as D2, which is responsible for muscle control and other feedback mechanisms. The rise of another drug, Cisapride, in the 1990’s put Reglan in the backseat; however, after the FDA determined Cisapride as one of the main causes of cardiac arrhythmia in January of 2000, it was taken off the shelves six months later. Reglan is now back in the limelight, especially for a Reglan lawyer, due to its association with tardive dyskinesia.

What is Reglan tardive dyskinesia?

In 1989, the A.H. Robins Company and American Home Product Corporation, manufacturers of Reglan, were brought before the US courts by a Reglan lawyer because of a patient complaining of Reglan tardive dyskinesia.  At the end of the Reglan lawsuit, the court’s ruling was that the patient should have been informed of the risks beforehand. Tardive dyskinesia is a condition in which the individual experiences muscle spasms and uncontrollable repetitive movements like face grimacing, rapid eye blinking, tongue protrusion, facial tics, and Restless Leg Syndrome (RLS). At present, there is no accepted cure or treatment for tardive dyskinesia and the fact that its symptoms are often irreversible adds to the severity of the condition.

Reglan tardive dyskinesia integrated in black box warning

In 2009, the FDA required the manufacturers of Reglan to put a black box warning on the drug’s label informing health practitioners of the risk of Reglan tardive dyskinesia. Manufacturers are now also required to use a Risk Evaluation and Mitigation Strategy (REMS) to make sure that patients are always provided with a medication guide discussing this risk. With more than 2 million Americans still using Reglan, it is important to determine whether patients being prescribed the drug are completely aware of tardive dyskinesia and the other risks involved in its use.